Loading...
Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF).
Arkenau, H Martin-Liberal, J Calvo, E Penel, N Krebs, Matthew G Herbst, R Walgren, R Widau, R Mi, G Jin, J
Arkenau, H
Martin-Liberal, J
Calvo, E
Penel, N
Krebs, Matthew G
Herbst, R
Walgren, R
Widau, R
Mi, G
Jin, J
Citations
Altmetric:
Abstract
Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is consistent with reports of other tumor cohorts within this phase Ia/b trial.Ramucirumab plus pembrolizumab did not demonstrate an improvement in overall survival when compared with historical controls in biomarker unselected, heavily pretreated patients with advanced or metastatic biliary tract cancer.Patients with programmed death-ligand 1 (PD-L1)-positive tumors had improved overall survival compared with patients with PD-L1-negative disease.
Description
Date
2018-05-31
Publisher
Collections
Files
Keywords
Type
Article
Citation
Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). 2018, Oncologist